✦ LIBER ✦

Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis

✍ Scribed by Plutzky, J.; Garber, A.; Falahati, A.; Toft, A.D.; Poulter, N.R.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PDB8 A Network Meta Analysis to Compare

✍ Scott, D.; Boye, K.S.; Timlin, L.; Best, J.H.; Clark, J. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

PDB70 BASELINE CHARACTERISTICS AND ANTID

✍ C. McAdam Marx; J. Bouchard; M. Aagren; C. Conner; D. Brixner 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

PRM40 Efficacy of Liraglutide Compared t

✍ Fadipe, J.J. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Glycaemic control and adverse events in

✍ J. Belsey; G. Krishnarajah 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 330 KB

OP5: Low Cardiovascular (CV) Risk Hazard

✍ Johansen, O.E.; Neubacher, D.; von Eynatten, M.; Patel, S.; Woerle, H.J. 📂 Article 📅 2012 🏛 Masson Editeur 🌐 French ⚖ 58 KB

Glycated Hemoglobin and Risk of Death in

✍ Hill, Christopher J.; Maxwell, Alexander P.; Cardwell, Christopher R.; Freedman, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 398 KB